- Home
- OM vs CRVS Comparison
OM vs CRVS Comparison
Compare OM & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OM
- CRVS
- Stock Information
- Founded
- OM 2003
- CRVS 2014
- Country
- OM United States
- CRVS United States
- Employees
- OM N/A
- CRVS N/A
- Industry
- OM Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- OM Health Care
- CRVS Health Care
- Exchange
- OM Nasdaq
- CRVS Nasdaq
- Market Cap
- OM 220.8M
- CRVS 305.4M
- IPO Year
- OM 2020
- CRVS 2016
- Fundamental
- Price
- OM $13.91
- CRVS $5.75
- Analyst Decision
- OM Hold
- CRVS Strong Buy
- Analyst Count
- OM 1
- CRVS 4
- Target Price
- OM $22.00
- CRVS $15.00
- AVG Volume (30 Days)
- OM 288.8K
- CRVS 518.7K
- Earning Date
- OM 08-06-2025
- CRVS 08-07-2025
- Dividend Yield
- OM N/A
- CRVS N/A
- EPS Growth
- OM N/A
- CRVS N/A
- EPS
- OM N/A
- CRVS N/A
- Revenue
- OM $119,304,000.00
- CRVS N/A
- Revenue This Year
- OM $12.37
- CRVS N/A
- Revenue Next Year
- OM $10.52
- CRVS N/A
- P/E Ratio
- OM N/A
- CRVS N/A
- Revenue Growth
- OM 2.47
- CRVS N/A
- 52 Week Low
- OM $5.85
- CRVS $2.54
- 52 Week High
- OM $25.35
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- OM 43.41
- CRVS 65.10
- Support Level
- OM $13.60
- CRVS $5.28
- Resistance Level
- OM $14.35
- CRVS $5.64
- Average True Range (ATR)
- OM 0.60
- CRVS 0.30
- MACD
- OM 0.26
- CRVS 0.03
- Stochastic Oscillator
- OM 80.09
- CRVS 77.70
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).